Understanding the Market | TRANSTHERA-B rises over 18% again, total market value surpasses HKD 50 billion, and the Phase II trial of Entrectinib for breast cancer is approved
TRANSTHERA-B's stock price rose over 18% again, reaching a new high of HKD 129.3, with a total market value exceeding HKD 50 billion. The current stock price is HKD 125, with a trading volume of HKD 151 million. The company's core product, Tengrutini, has received approval from the National Medical Products Administration of China for its Phase II clinical trial targeting recurrent or metastatic breast cancer, demonstrating unique therapeutic value and gaining recognition from regulatory agencies in multiple countries
According to Zhitong Finance APP, TRANSTHERA-B (02617) has risen over 18% again, reaching a new high of HKD 129.3, with a total market value briefly surpassing HKD 50 billion. As of the time of writing, it has increased by 15%, trading at HKD 125, with a transaction volume of HKD 151 million.
In terms of news, TRANSTHERA recently announced that its core product Tinengotinib (TT-00420) in combination with Fulvestrant for the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative or low-expressing (HER2-) recurrent or metastatic breast cancer has received clinical implicit approval from the National Medical Products Administration of China on September 10, 2025.
TRANSTHERA stated that Tinengotinib targets FGFR/VEGFR, JAK, and Aurora, and currently, there are no other MTK inhibitors with the same targeted combination. Therefore, Tinengotinib has already demonstrated unique value in the treatment of certain diseases. Additionally, this product is gradually paving the way for globalization, having received breakthrough therapy designation for the treatment of cholangiocarcinoma from the National Medical Products Administration (NMPA) and fast track designation for the treatment of cholangiocarcinoma and metastatic castration-resistant prostate cancer from the U.S. Food and Drug Administration (FDA), as well as orphan drug designation for the treatment of cholangiocarcinoma from the FDA, and orphan drug designation for the treatment of biliary tract cancer from the European Medicines Agency (EMA)
